Research programme: progesterone intranasal - BHR Pharma

Drug Profile

Research programme: progesterone intranasal - BHR Pharma

Alternative Names: BHR-310

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BHR Pharma
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Apoptosis inhibitors; GABA modulators; Glutamate-antagonists; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Lipid peroxidation inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Brain injuries

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Brain injuries in USA (Intranasal, Spray)
  • 24 Jul 2012 Preclinical trials in Brain injuries in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top